# David A. Roth

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-a-roth/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,899 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 55 |
| i10-index | 132 |
| Last Known Institution | GlaxoSmithKline (United States) |
| OpenAlex ID | https://openalex.org/A5034488510 |
| ORCID iD | 0000-0001-8356-0457 |
| Works | 284 |

## Researcher papers

Showing 12 of 13.

- [A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation](https://scholariq.org/papers/a-more-accurate-method-to-estimate-glomerular-filtration-rate-from-serum/)
- [Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis](https://scholariq.org/papers/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis/)
- [Sequential Therapies for Proliferative Lupus Nephritis](https://scholariq.org/papers/sequential-therapies-for-proliferative-lupus-nephritis/)
- [The evaluation of renal transplantation candidates: clinical practice guidelines.](https://scholariq.org/papers/the-evaluation-of-renal-transplantation-candidates-clinical-practice-guidelines/)
- [Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study](https://scholariq.org/papers/efficacy-and-safety-of-subcutaneous-belimumab-in-systemic-lupus-erythematosus-a/)
- [Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response](https://scholariq.org/papers/belimumab-in-the-treatment-of-systemic-lupus-erythematosus-high-disease-activity/)
- [Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A](https://scholariq.org/papers/nonviral-transfer-of-the-gene-encoding-coagulation-factor-viii-in-patients-with/)
- [Treadmill running produces both positive and negative physiological adaptations in Sprague-Dawley rats](https://scholariq.org/papers/treadmill-running-produces-both-positive-and-negative-physiological-adaptations/)
- [A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea](https://scholariq.org/papers/a-pivotal-phase-iii-randomised-placebo-controlled-study-of-belimumab-in-patients/)
- [2 CURRENT CONCEPTS IN LACTATE EXCHANGE](https://scholariq.org/papers/2-current-concepts-in-lactate-exchange/)
- [Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression](https://scholariq.org/papers/systemic-lupus-erythematosus-lupus-nephritis-and-end-stage-renal-disease-a/)
- [A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis](https://scholariq.org/papers/a-secondary-analysis-of-the-belimumab-international-study-in-lupus-nephritis/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Hemophilia Treatment and Research](https://scholariq.org/topics/hemophilia-treatment-and-research/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [GlaxoSmithKline (United States)](https://scholariq.org/institutions/glaxosmithkline-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.